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Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the 
gastrointestinal tract associated with altered composition of the gut microbiota. Lactobacillus 
reuteri BR11 (BR11) has recently been reported to reduce the severity of experimental IBD 
with its probiotic properties possibly attributed to a mechanism of thiol production via its 
unique cysteine/cystine transport system.  
Aim: We compared BR11 and a BR11 mutant deficient in the cystine uptake system 
(PNG201), for their capacity to reduce the severity of experimental colitis. 
Methods: Male Sprague Dawley rats (n=8 per group) were gavaged (1 ml/day) with skim 
milk, BR11 or PNG201 (1 x 10
9
 CFU/ml) for 12 days. Rats consumed either water or 2% 
dextran sulfate sodium (DSS) in drinking water from days 6 to 12 to induce colitis. 
Metabolism data, disease activity index (DAI), intestinal mucin profile and histological 
analyses were assessed and compared by ANOVA. 
Results: Assessed histologically, DSS administration resulted in significant colonic 
deterioration, including loss of crypt area and increased damage severity. BR11 
administration only partially alleviated the DSS effects, with a minor improvement in crypt 
area (p<0.05). Administration of the PNG201 mutant strain to colitic animals failed to 
achieve significance (p>0.05) against the DSS control for any of the end-point parameters. 
However, the mutant strain induced a significantly greater (p<0.05) histological severity 
compared to BR11 treated colitic animals, representing a possible exacerbation of colitis. 
Conclusions: The cystine uptake system only minimally influences the biological effects of 
BR11, as evidenced by histological and macroscopic colitic changes.  
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Inflammatory bowel disease (IBD) refers to an assemblage of chronic intestinal inflammatory 
disorders with an incidence of approximately 1 in 9-10000 [1]. The etiology of IBD is not 
fully understood. However, aside from a genetic predisposition, contributing factors include 
environmental, immunological and microbial influences [2]. The pathology of IBD is 
characterized by damage to the gastrointestinal epithelium and mucosa, resulting in 
ulceration, inflammation and hemorrhage. 
 
Current pharmaceutical treatment options for IBD are relatively ineffective; consequently 
investigations into alternative treatment options have increased. Probiotics, strains of living 
bacteria that confer positive effects when administered in sufficient quantities [3], represent 
one such option. A wide array of probiotic strains, and combinations thereof, have been 
investigated with varied degrees of success to identify the most effective treatment options 
for IBD, and also to better understand their modes of action [4-6]. These bacterial strains are 
believed to exert their beneficence through a number of different mechanisms, most of which 
are not completely understood [7,8]. These mechanisms include competition with pathogens, 
modulation of the intestinal immune system, maintaining homeostasis of the intestinal 
epithelium, promoting crypt cell proliferation, inhibition of cell apoptosis and reduction of 
pro-inflammatory cytokine expression [4,7,9-12]. 
 
Lactobacillus reuteri BR11 (BR11) is a bacterial strain ((formerly Lactobacillus fermentum 
BR11) with unique antioxidant properties [13] that has shown promise in the treatment of 
experimental colitis [14]. BR11 efficacy is proposed to be mediated through its unique 
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cystine transport system [13,15,16]. This transport system is responsible for transporting 
exogenous cystine into the bacterial cell and expelling the thiol products, which diminish the 
effects of oxidative stress by detoxifying reactive oxygen species present [17]. Oxidative 
stress is one of the main factors influencing intestinal injury in IBD [18], with recent studies 
suggesting that probiotic administration can attenuate oxidative stress in rats [19]. The uptake 
system of L. reuteri BR11 comprises a high affinity cystine binding protein termed Cystine 
Uptake C (CyuC), a component of the ATP binding cassette cystine transport system [20]. In 
order to determine the role of this unique system, the cyuC gene was inactivated using 
homologous recombination to produce a L. reuteri mutant (PNG201) deficient in cystine 
uptake [13,21]. Utilizing a rat model of colitis induced by ingesting dextran sulfate sodium 
(DSS) it was hypothesized that elimination of the CyuC protein, which effectively inactivates 






Materials and Methods 
Bacterial preparations 
L. reuteri BR11, and the CyuC deficient strain PNG201, were both kind gifts from Professor 
Philip Giffard and Dr Mark Turner, Queensland University of Technology (Queensland, 
Australia). L. reuteri BR11, originally isolated from the vaginal tract of a guinea pig [22], and 
L. reuteri PNG201, a CyuC deficient mutant developed using homologous recombination 
[13], were grown on Mann Rogosa Sharp (MRS) agar and broths (Oxoid, Hampshire, 
England) with or without the antibiotic, erythromycin (10 µg/ml). As PNG201 was developed 
to be resistant to erythromycin, culturing the mutant in the presence of this antibiotic ensured 
the mutant had not reverted to wild-type, and allowed for an uncontaminated specimen. Both 
were incubated under anaerobic conditions and incubated at 37°C. The bacteria were grown 
to concentrations of approximately 1×10
9
 colony forming units (CFU)/ml, dissolved in 10% 
skim milk powder and stored at -20°C until required. 
 
Animal trial 
The animal trial was performed in compliance with The Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes, and was approved by the Animal Care and 
Ethics Committee of the University of Adelaide. Male Sprague Dawley rats (n=48; 120-160 
g) were housed individually in metabolism cages (Tecniplast, PA, USA) at a room 
temperature of 22°C with a 12 light:dark cycle. Throughout the duration of the trial the rats 
were provided ad libitum access to a standard 18% casein diet [23] and water. All animals 
were acclimatized for two days prior to experimentation. Metabolism parameters including 
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body weight, food and water intake, and fecal and urine output were monitored and measured 
daily. 
 
Rats were randomly allocated to one of six treatment groups (n=8 rats/treatment); Water + 
Vehicle, Water + BR11, Water + PNG201, dextran sulfate sodium (DSS) + Vehicle, DSS + 
BR11 and DSS + PNG201. L. reuteri BR11 solution (1 ml) or vehicle (skim milk) was 
administered once daily via oral gavage from day 1 to 12. Between days 6 and 12, 
experimental colitis was induced via the addition of 2% DSS (ICN Biomedical, CA, USA) to 
the drinking water. 
 
Disease severity was monitored daily, based on a disease activity index (DAI), scoring 
overall animal condition, weight loss, stool consistency and rectal bleeding on a scale from 0-
3 for each parameter between days 7 and 12 (0 being healthy and 3 being severely affected) 
[24]. At day 12, all rats were sacrificed by carbon dioxide asphyxiation and cervical 
dislocation prior to dissection. Following sacrifice, the lengths of the gastrointestinal organs 
were measured un-stretched, and all internal organs were emptied of contents, if necessary, 
and weighed. Separate 2 cm segments of proximal and distal colon were removed and placed 
in 10% buffered formalin for histological analysis and 4 cm segments were snap-frozen in 
liquid nitrogen and stored at -80°C for biochemical analysis. 
 
Histological analysis 
Segments (2 cm) of the proximal and distal colon were routinely processed and embedded in 
paraffin wax. Sections (4 µm) were then cut and stained with hematoxylin and eosin. Severity 
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of intestinal damage was assessed using a quantitative analysis based on the parameters of 
surface enterocyte disruption, goblet cell numbers, crypt disruption, crypt abscess formation, 
polymorphonuclear cell infiltration, submucosal thickening and submuscularis externa 
thickening [25]. A score of 0 (unaffected) to 3 (severe damage) was recorded for each 
parameter to give an overall disease severity score, which was expressed as a median score 
(range). Both crypt loss and lengthening are common features of the DSS-colitis model [26]. 
Measurements of crypt depth in the proximal and distal colon were also determined, using 40 
crypts per tissue section per rat to obtain a mean value [27]. Crypt area was calculated for the 
distal colon using three tissue sections per rat to obtain a mean value. All analyses were 
performed in a blinded fashion, using an Olympus BH-2 light microscope (Tokyo, Japan) 
with Sony digital camera (Tokyo, Japan) and Image Pro Plus Software Package Version 
4.5.1.27 (Media Cybernetics, MD, USA). 
 
Mucin characterization 
The heterogeneous oligosaccharide chains of mucin glycoproteins provide potential binding 
sites for both commensal and pathogenic organisms, and may perform a defensive role as a 
protective barrier during periods of mucosal injury [28]. Derangement of this barrier has been 
linked to the pathophysiology of ulcerative colitis [29]. Colonic sections from each animal 
were stained with periodic acid-Schiff (PAS) [30]. Sections were subjected to mild acid 
hydrolysis to eliminate the contribution of sialic acid residues before PAS staining. Sections 
were immersed in periodic acid solution (Sigma, St. Louis, MO, USA) for 20 min, washed, 
and immersed in Schiff’s Reagent (Sigma) for a further 20 min. Sections were rinsed in tap 
water for 10 min, dehydrated, and mounted in Entellan (ProSciTech, Kirwan, Queensland, 
Australia). Stained sections were examined by light microscopy with an Olympus CX41 
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microscope (Olympus, Tokyo, Japan) using a 20× objective and digital colour images [super 
high quality (2080 × 1544 pixels)] captured using an Olympus U-CAMD3 wide-zoom 
camera. Image analysis program analySIS® FIVE (Olympus Soft Imaging Solutions GmBH, 
Germany) was used to measure the parameters for each of the stained sections. The number 
of goblet cells per unit of epithelial area (mm
2
) was calculated.  
 
Statistical analysis 
Statistical analysis was performed using the SPSS 15.0 software package (SPSS Inc. 
Chicago, IL, USA). Histological damage severity was expressed as a median value while all 
other data was expressed as a mean ± SEM. Comparisons of data between treatment groups 
was performed using a one-way ANOVA, with a Tukey’s post hoc test, while DAI data was 
analyzed using repeated measure ANOVA with a Tukey’s post hoc test. Qualitative analysis 





No significant difference (p>0.05) in weight gain was evident among the water or DSS 
treated groups, except for DSS + PNG201 in which the weight gain was significantly reduced 
(p<0.05) compared to healthy control rats (Table 1). Food and water consumption remained 
similar (p>0.05) across the groups over the course of the experimental period, with no 
influence of treatments. While there was no significant difference in urine or fecal output in 
the water-treated groups (p>0.05, Table 1), DSS consumption increased fecal production 
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(p<0.05) for BR11 (29%) and PNG201 (25%) treated groups compared to healthy controls 
(water + skim milk). Urine output for all DSS treated animals decreased (p<0.001) 
remarkably (by ~40%) compared to water controls. 
 
Disease activity index (DAI) 
An increase in DAI is usually evident in the DSS-induced model of colitis [14]. On days 8, 
10 and 11 DAI was significantly greater (p<0.05) in DSS + PNG201 compared to healthy 
controls. On day 12, DAI was significantly greater in DSS-treated rats receiving  BR11 
compared to healthy control rats, with DSS + PNG201 highly significant (p<0.001) compared 
to healthy controls (Figure 1). 
 
Organ weights and lengths 
Organ weights were expressed as a proportion of total body weight to correct for differences 
in body weight. There was no significant difference (p>0.05) observed in the fractional 
weights of any of the visceral organs (heart, lungs, left kidney, right kidney, liver, spleen and 
thymus) among the treatment groups as a result of BR11, PNG201 or DSS administration 
compared to normal controls (data not shown). Similarly, administration of neither bacterial 
strain nor DSS failed to impart any significant influence (p>0.05) on the lengths of the 
duodenum and small intestine.  However, the length of the colon was significantly reduced 
(p<0.05) in DSS-treated rats receiving BR11 (18%) and PNG201 (20%) compared to healthy 
controls (Table 2). This was accompanied by a significantly greater (28%; p<0.05) weight of 
the colon in DSS-treated rats receiving PNG201 when compared to water drinking controls. 
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Nonetheless, weights of all other gastrointestinal organs (stomach, duodenum, small intestine 
and cecum) were not altered significantly in any of the treatment groups (Table 2). 
 
Histological analysis 
The damage severity score in the proximal and distal colon was significantly greater 
(p<0.001) following DSS consumption compared to the healthy controls (Table 3). 
Interestingly, the severity scoring for DSS + PNG201 was significantly greater (p<0.05) than 
DSS + BR11 in the distal colon. There was no significant (p>0.05) effect exerted by either 
bacterial strain (BR11: 215 ± 24 µm, PNG201: 198 ± 23 µm) or DSS consumption (252 ± 11 
µm) on crypt depth compared to the water treated controls (210 ± 11 µm) in the distal colon. 
Crypt area in the distal colon was not affected by BR11 or PNG201 administration in healthy 
animals, however it was significantly (p<0.05) decreased in the DSS control and DSS + 
PNG201 compared to the water treated controls (Figure 2) such that there was no significant 
difference between the DSS + BR11 treatment group and healthy controls (p>0.05). 
 
Mucin characterization 
Numbers of neutral mucin containing goblet cells in the colon were not significantly 





; Water + BR11: 4.74 ± 0.40; Water + PNG201: 4.96 ± 0.70; DSS + 






While the novel antioxidant mechanism of L. reuteri BR11 has been examined extensively in 
vitro, the contribution of the cystine uptake transport system to probiotic activity has not been 
investigated in vivo. BR11 has been tested for therapeutic efficacy primarily using the DSS-
colitis model. As such, we utilized this model to investigate the role of the cystine uptake 
system to better define its contribution to the effects conferred by BR11. 
 
In the present study, DSS consumption resulted in moderate damage to the proximal and 
distal colon, observed through histological scoring, increased fecal production and a 
progressively increasing DAI score during the period of DSS consumption, including the 
presence of diarrhea, and rectal bleeding in later stages. Consumption of DSS is known to 
impart histological changes in the colon, including an elevated damage severity score, 
lengthening of crypts and crypt loss [26], often in conjunction with significant shortening of 
the colon [31]. Crypt lengthening and crypt loss are also commonly observed indicators of 
DSS-induced colitis [32], however, only crypt loss was observed in the current study. 
Lengthening of crypts is believed to be a compensatory mechanism to maximize absorptive 
function during periods of damage and repair, the absence of this feature in the current study 
may therefore have been related to the severity of DSS-induced damage or the timing of the 
measurement. 
 
In the current study, administration of BR11 did not significantly alter any assessed 
parameters compared to the DSS-treated colitic control, whilst administration of PNG201 
produced minimal changes compared to wild-type BR11, namely, an elevated intestinal 
15 
 
severity score in the distal colon. Based on this finding, we can speculate that the presence or 
absence of CyuC has minimal impact on the mode of action of BR11 in the current setting. It 
should be noted however that rats treated with PNG201 displayed increased colon weight, 
reduced body weight and reduced crypt area compared to healthy control rats, findings that 
were not reflected in the BR11 treated rats. This may provide some indication that the 
PNG201 treated rats were affected by DSS to a greater extent than their BR11 treated 
counterparts.  Since the DSS-colitis control group failed to reach significance against the 
healthy controls for many of the measured parameters it could be surmised that the challenge 
provided by the DSS in the current trial was reflective of very low grade colitis. As such, the 
significance of the cystine uptake system to the possible probiotic properties of BR11 could 
not be determined with certainty. As the severity of colitis was relatively low, it was difficult 
to discern whether the bacterial strains acted as hypothesized, with BR11 partially 
normalizing crypt area, but failing to reduce overall damage severity in the colon. 
 
As responses to DSS are dose-dependent [33], in future studies a higher dosage of DSS in the 
drinking water could induce colitis of greater severity to fully evaluate the role of the cystine 
uptake system. Previously, an appropriate disease severity was achieved by administering 
DSS at 2% to Sprague Dawley rats for seven days [14]. This DSS concentration was 
consistent with the current study; however, rats were exposed to DSS for only six days. 
Although some animals responded as expected, with progressively worsening diarrhea and 
anal bleeding, others displayed no overt clinical signs of disease for the duration of the 




While BR11 in the current study was able to partially prevent crypt loss, there was no 
significant ameliorating effect exerted across any of the other parameters. To this end, both 
the BR11 wild-type and the PNG201 mutant failed to achieve statistical significance 
compared to the colitis control for all measured parameters.  Probiotics, unlike conventional 
treatments, are living organisms, and thus their effects within the body can be variable. The 
reduced bioactivity of the BR11 wild-type in the current study was in contrast to the study 
conducted by Geier et al. [14], in which BR11 was found to reduce disease activity and 
histological severity, prevent colon shortening and was able to normalize weight gain and 
food intake, all of which were significantly affected in the DSS-treated controls. A possible 
reason for these differences may have been the concentration of bacteria administered to the 
animals. In the study by Geier et al. [14] the bacteria were grown to a concentration of 1-
2×10
10
 CFU/ml, while in the current study bacterial concentrations were tenfold lower (1×10
9
 
CFU/ml). In support of this hypothesis, animal studies using BR11 in a model of 5-FU 
induced intestinal mucositis have failed to achieve beneficial results using lower or similar 
BR11 concentrations. One study comparing three different bacterial strains using 
concentrations of 1×10
6
 CFU/ml failed to improve any of the assessed parameters, despite 
previous studies indicating their potential [34]. Another study investigating BR11 at 
concentrations of 1×10
9
 CFU/ml, also failed to achieve any significant beneficial results [35]. 
However, it should be noted that a higher DSS dose (3%) was also used by Geier et al. [35].  
 
The lack of efficacy observed in other studies indicates that BR11 may only prove to be an 
effective probiotic at high (~1×10
10
 CFU/ml) concentrations, which would suggest the 
bacterial concentration levels in the current study may have been insufficient. Additionally, 
any decreased function in the PNG201 mutant would only be observed at higher 
concentrations. As such, future studies could benefit from the administration of higher 
17 
 
concentrations of BR11 and the PNG201 mutant strain. Although it was routinely cultured in 
the presence of erythromycin, the possibility still exists that the PNG201 mutant may have 
reverted back to the wild-type in the animals in the absence of erythromycin selection. In 
future studies, culturing the bacterial population in the feces, on MRS agar + erythromycin, 
could be utilized to monitor the stability and/or survival of the mutant.  
 
In conclusion, in the current study, neither the wild-type BR11, nor a CyuC deficient strain of 
L. reuteri could prevent the development of experimental colitis in rats. However, rats 
administered the PNG201 BR11 mutant strain displayed some indications of a minor 
exacerbation of colitis compared to the wild-type strain. Nevertheless, the challenge provided 
by the DSS, and possibly the concentration of the bacterial treatments, may have been sub-
optimal to provide conclusive evidence regarding the contribution of the cystine uptake 
system to the mechanism of action of BR11. Further studies utilizing BR11 are required to 
clarify the conflicting results observed in previous studies of BR11 in the contexts of colitis 
and mucositis to definitively classify BR11 as a probiotic.  
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Table 1. Effect of Lactobacillus reuteri BR11 and its mutant PNG201 on metabolic attributes 
of rats following DSS administration 
 Water+SM Water+BR11 Water+PNG201 DSS+SM DSS+BR11 DSS+PNG201 
Weight gain (g) 49.1 ± 1.0 47.7 ± 1.6 47.9 ± 0.9 42.0 ± 1.3 40.6 ± 3.7 39.2 ± 2.5* 
Food intake (g) 144.1 ± 3.4 143.3 ± 3.8 140.0 ± 1.9 130.4 ± 2.7 133.1 ± 4.3 130.6 ± 3.2 
Water intake (ml) 267 ± 23 240 ± 18 253 ± 18 210 ± 15 230 ± 16 220 ± 18 
Fecal output (g) 11.2 ± 0.3 11.6 ± 0.7 11.3 ± 0.6 13.6 ± 0.6 14.4 ± 0.8* 14.0 ± 0.9* 
Urine output (ml) 129 ± 8 123 ± 9 129 ± 7 77 ± 3*** 79 ± 4*** 78 ± 2*** 
n=8 rats/treatment. Data are expressed as mean ± SEM. Skim milk (SM) as vehicle. 






Table 2. Effect of Lactobacillus reuteri BR11 and its mutant PNG201 on gastrointestinal 
organ lengths and weights of rats following DSS administration 
 Water+SM Water+BR11 Water+PNG201 DSS+SM DSS+BR11 DSS+PNG201 
Length (cm)       
Duodenum 7.8 ± 0.2 7.4 ± 0.1 7.3 ± 0.2 7.7 ± 0.3 7.7 ± 0.1 7.9 ± 0.4 
Small Intestine 83.1 ± 2.7 81.4 ± 1.3 82.1 ± 1.6 82.5 ± 2.0 80.8 ± 1.8 83.4 ± 1.7 
Colon 14.5 ± 0.6 14.3 ± 0.4 14.6 ± 0.4 12.8 ± 0.4 11.9 ± 0.4* 11.7 ± 0.4* 
Weight        
Stomach 54.8 ± 1.0 58.4 ± 1.5 56.3 ± 2.0 59.5 ± 1.2 61.7 ± 3.1 58.2 ± 1.4 
Duodenum 28.8 ± 1.2 28.5 ± 1.0 26.9 ± 1.4 29.8 ± 1.2 28.4 ± 1.2 28.3 ± 1.4 
Small Intestine 220 ± 4 217 ± 5 216 ± 4 221 ± 3 230 ± 5 225 ± 2 
Cecum 41.9 ± 2.6 44.6 ± 2.8 39.0 ± 1.8 38.2 ± 2.1 40.7 ± 2.3 42.9 ± 2.8 
Colon 38.3 ± 1.2 39.2 ± 1.7 37.4 ± 1.8 45.6 ± 1.9 47.6 ± 2.8 49.0 ± 4.1* 
n=8 rats/treatment. Length data are expressed as mean (cm) ± SEM. Weight data are 
expressed as mean (x10
-2
% relative to body weight) ± SEM. Skim milk (SM) as vehicle. 
*Indicates p<0.05 significance to Water+SM.  
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Table 3. Effect of Lactobacillus reuteri BR11 and its mutant PNG201 on histological 
damage severity scores in the proximal colon of rats following DSS administration 
 
 Water+SM Water+BR11 Water+PNG201 DSS+SM DSS+BR11 DSS+PNG201 














Data are expressed as median score with range in parentheses. Skim milk (SM) as vehicle. 







Figure 1. Disease Activity Index (DAI) between days 7-12 during the development of 
DSS-induced colitis in rats (n=8 rats/treatment). Data are expressed as mean ± 
SEM. *p<0.05 and ***p<0.001 compared to water+Vehicle (skim milk). 
 
Figure 2.  Measurements of crypt area in distal colon in rats (n=8 rats/treatment). Data 
are expressed as mean (mm
2
) ± SEM. *p<0.05 compared to water+ Vehicle 
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